Detalhe da pesquisa
1.
SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion.
Cell
; 187(4): 861-881.e32, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38301646
2.
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages.
Cell
; 184(11): 2988-3005.e16, 2021 05 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019793
3.
The composition and signaling of the IL-35 receptor are unconventional.
Nat Immunol
; 13(3): 290-9, 2012 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22306691
4.
BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
J Pathol
; 256(2): 223-234, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34731491
5.
PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Gastroenterology
; 160(3): 781-796, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33129844
6.
Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Prostate
; 81(6): 326-338, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33636027
7.
LAG3 (CD223) as a cancer immunotherapy target.
Immunol Rev
; 276(1): 80-96, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28258692
8.
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Prostate
; 80(16): 1429-1437, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32949185
9.
Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Prostate
; 80(4): 336-344, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31899823
10.
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Prostate
; 80(14): 1159-1176, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32779781
11.
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
J Urol
; 204(2): 247-253, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32118506
12.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
J Immunol
; 200(2): 375-383, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29311378
13.
A role for paracrine interleukin-6 signaling in the tumor microenvironment in prostate tumor growth.
Prostate
; 79(2): 215-222, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30345534
14.
Consequences of interleukin 1ß-triggered chronic inflammation in the mouse prostate gland: Altered architecture associated with prolonged CD4+ infiltration mimics human proliferative inflammatory atrophy.
Prostate
; 79(7): 732-745, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30900284
15.
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.
Am J Pathol
; 188(6): 1478-1485, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29577933
16.
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Future Oncol
; 15(15): 1683-1695, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30968729
17.
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Proc Natl Acad Sci U S A
; 113(48): E7769-E7777, 2016 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27837027
18.
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.
Lancet Oncol
; 19(1): 76-86, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29248236
19.
Expression of LAG-3 and efficacy of combination treatment with anti-LAG-3 and anti-PD-1 monoclonal antibodies in glioblastoma.
Int J Cancer
; 143(12): 3201-3208, 2018 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30248181
20.
Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization.
Cancer Immunol Immunother
; 67(10): 1491-1503, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30030559